Know Cancer

forgot password

A Phase I Open Label Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1/Phase 2
18 Years
Not Enrolling
Refractory Multiple Myeloma

Thank you

Trial Information

A Phase I Open Label Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma

Inclusion Criteria:

- Advanced Multiple Myeloma.

- Progression after ≥ 2 lines of prior therapy, including at least one steroid, one
immunomodulatory agent (iMID), one alkylator, and bortezomib (VELCADE®).

- ECOG performance status of either 0 or 1.

Exclusion Criteria:

- Prior chemotherapy with antimicrotubule agents

- Metastasis involving the brain or spinal cord

- Clinically significant lung or heart disease

- Abnormal electrocardiogram

Please note that there are additional inclusion and exclusion criteria. The study center
will determine if you meet all of the criteria.

Site personnel will explain the trial in detail and answer any question you may have if
you do qualify for the study. You can then decide whether or not you wish to participate.
If you do not qualify for the trial, site personnel will explain the reasons.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To determine the maximum tolerated dose

Outcome Time Frame:

During the first 28 day treatment cycle

Safety Issue:



United States: Food and Drug Administration

Study ID:




Start Date:

November 2007

Completion Date:

July 2010

Related Keywords:

  • Refractory Multiple Myeloma
  • Refractory Multiple Myeloma
  • CB3304
  • Noscapine HCl
  • Multiple Myeloma
  • Multiple Myeloma
  • Neoplasms, Plasma Cell



Weill Medical College of Cornell University New York, New York  10021
Columbia Presbyterian Hospital New York, New York  10032
St. Vincent's Comprehensive Cancer Center New York, New York  10011
UCLA Los Angeles, California  90095